Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.65 |
| ▸ | CTSB | P07858 | 6/20 | 0.65 |
| ▸ | CTSS | P25774 | 6/20 | 0.65 |
| ▸ | CTSK | P43235 | 4/20 | 0.65 |
| ▸ | CTSD | P07339 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840958 | 0.93 | CTSL (0.73) | CTSLCTSBCTSSCTSKCTSD | |
| Bromide SCHEMBL1840991 | 0.92 | CTSL (0.71) | CTSLCTSBCTSSCTSKCTSD | |
| Hydrochloric Acid SCHEMBL1839057 | 0.92 | CTSL (0.71) | CTSLCTSBCTSSCTSKCTSD | |
| Acetic Acid SCHEMBL1839653 | 0.91 | CTSL (0.70) | CTSLCTSBCTSSCTSKCTSD | |
| SCHEMBL1849749 | 0.89 | CTSL (0.62) | CTSLCTSBCTSSCTSKCTSD | |
| Fumaric Acid SCHEMBL1838246 | 0.88 | CTSL (0.67) | CTSLCTSBCTSSCTSKCTSD | |
| Fumaric Acid SCHEMBL1838249 | 0.88 | CTSL (0.67) | CTSLCTSBCTSSCTSKCTSD | |
| SCHEMBL1840742 | 0.85 | CTSL (0.58) | CTSLCTSBCTSSCTSKCTSD | |
| Citric Acid SCHEMBL1838885 | 0.84 | CTSL (0.61) | CTSLCTSBCTSSCTSKCTSD | |
| SCHEMBL1840743 | 0.83 | CTSL (0.61) | CTSLCTSBCTSSCTSKCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8481725-B2 | Cycloalkylcarbonylamino acid derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| EP-1975162-B1 | OXAZOLONE DERIVATIVE | SEIKAGAKU KOGYO CO LTD (JP) | 2012-08-15 | — | — | EP | disclosed |
| EP-1972636-B1 | CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU KOGYO CO LTD (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-2036920-B1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU KOGYO CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20090137799-A1 | Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2036920-A1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-1975162-A1 | OXAZOLONE DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-1972636-A1 | CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131661-A1 | Oxazolone Derivatives | CTSK, CTSZ, CTSV | CTSL 7/4885CTSB 5/4885CTSS 4/4885 |
| US-20090137799-A1 | Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same | CTSK, CTSS, CTSE | CTSL 9/4885CTSB 6/4885CTSS 2/4885 |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | CTSK, CTSS, CTSV | CTSL 9/4885CTSB 6/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.